Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Eliav Gov-Ari

Pediatric Otolaryngology Columbia, MO Medical Doctor

NPI 1508868951 CMS profile 1032652

812 N Keene St, Columbia, MO 65201

Open in the dashboard

General payments

$1,955

105 records reported · program years 2019–2024

Research payments

$0

Paid to them · None reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Eliav Gov-Ari of Columbia, MO is reported in the CMS Open Payments database as having received $1,955 across 105 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Pediatric Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $141 8
2023 General $583 29
2022 General $376 20
2021 General $318 15
2020 General $293 18
2019 General $243 15

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eliav Gov-Ari
  • Pediatric Otolaryngology median
  • Middle half of Pediatric Otolaryngology
  • National median

In program year 2025, general payments to Eliav Gov-Ari were reported at $0. Among 368 Pediatric Otolaryngology profiles paid that year, the median was $172 and the middle half received between $78 and $412.

Show as a table
Year Eliav Gov-Ari Pediatric Otolaryngology median Middle half National median
2019 $243 $127 $51–$271 $163
2020 $293 $64 $31–$165 $114
2021 $318 $88 $26–$225 $132
2022 $376 $122 $43–$316 $149
2023 $583 $128 $52–$340 $160
2024 $141 $150 $65–$384 $164
2025 $0 $172 $78–$412 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $721 45 payments
  2. Genzyme Corporation $335 19 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $249 10 payments
  4. KARL STORZ Endoscopy-America $168 4 payments
  5. Novartis Pharmaceuticals Corporation $115 7 payments
  6. Genentech USA, Inc. $64 3 payments
  7. Grifols USA, LLC $52 3 payments
  8. AstraZeneca Pharmaceuticals LP $52 3 payments
  9. BioCryst US Sales Co., LLC $45 2 payments
  10. ALK-Abello, Inc $41 2 payments
  11. Other $113 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $1,938 104 payments
  2. Education $16 1 payment
Products named General payments · program years 2019–2024
  1. DUPIXENT Immunology $668 38 payments
  2. NUCALA Immunology $496 30 payments
  3. NUCALA Respiratory $225 15 payments
  4. HYQVIA $218 8 payments
  5. DUPIXENT Immunology $79 5 payments
  6. n.a. $68 1 payment
  7. Xolair Immunology $64 3 payments
  8. XOLAIR Pulmonary/Respiratory Diseases $61 3 payments
  9. XOLAIR Respiratory $54 4 payments
  10. Xembify $52 3 payments
  11. Other $302 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

105 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Otolaryngology in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record